Volume 16, Issue 7 pp. 726-735
Original Report

The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months

Björn Wettermark M.Sc.Pharm, PhD

Corresponding Author

Björn Wettermark M.Sc.Pharm, PhD

Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge. WHO collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, and Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden

National Corporation of Pharmacies (Apoteket AB), Stockholm, Sweden

Board member, Swedish Society for Pharmacoepidemiology.

Apoteket AB, 131 88 Stockholm, Sweden.Search for more papers by this author
Niklas Hammar

Niklas Hammar

Assoc. professor

Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

Department of Epidemiology, AstraZeneca Research and Development, Mölndal, Sweden

Board member, Swedish Society for Pharmacoepidemiology.

Search for more papers by this author
C. MichaelFored MD, PhD

C. MichaelFored MD, PhD

Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, and Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden

Board member, Swedish Society for Pharmacoepidemiology.

Search for more papers by this author
Andrejs Leimanis

Andrejs Leimanis

Centre for Epidemiology, Swedish National Board of Health and Welfare, Stockholm, Sweden

Search for more papers by this author
Petra Otterblad Olausson PhD

Petra Otterblad Olausson PhD

Centre for Epidemiology, Swedish National Board of Health and Welfare, Stockholm, Sweden

Search for more papers by this author
Ulf Bergman MD, professor

Ulf Bergman MD, professor

Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge. WHO collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, and Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden

Search for more papers by this author
Ingemar Persson MD, professor

Ingemar Persson MD, professor

Medical Products Agency, Uppsala, Sweden

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

Search for more papers by this author
Anders Sundström MD, PhD

Anders Sundström MD, PhD

Swedish Association of Senior Citizens, Stockholm, Sweden

Search for more papers by this author
Barbro Westerholm MD, professor

Barbro Westerholm MD, professor

Swedish Association of Senior Citizens, Stockholm, Sweden

Search for more papers by this author
Måns Rosén MD, professor

Måns Rosén MD, professor

Centre for Epidemiology, Swedish National Board of Health and Welfare, Stockholm, Sweden

Search for more papers by this author
First published: 09 August 2006
Citations: 1,414

No conflict of interest was declared.

Abstract

Purpose

To describe the content and potentials of the new Swedish national register on prescribed and dispensed medicines.

Methods

The Swedish Prescribed Drug Register contains information about age, sex and unique identifier of the patient as well as the prescriber's profession and practice. Information regarding drug utilization and expenditures for prescribed drugs in the entire Swedish population was extracted from the first six months July–December 2005 and compared with total drug sales in the country including OTC and hospital use.

Results

The total quantity of drugs sold in Sweden was 2666 million DDDs, corresponding to 1608 DDD/1000 inhabitants daily. The total expenditures were 1.6 billion Euro. The prescribed drugs, included in the register, accounted for 84% of the total utilization and 77% of the total expenditures. About half of all men and two-thirds of all women in the country purchased drugs. The proportion increased by age. The most common drugs for chronic treatment were diuretics among women (8.8% of the population) and antithrombotic agents among men (7.6%). Psychotropic drugs, corticosteroids and analgesics were more common among women, while men used antithrombotic agents, antidiabetic drugs, lipid lowering agents and ACE inhibitors to a greater extent.

Conclusions

The new register provides valuable data on exposure to drugs and is useful to study patterns of drug utilization. The possibilities for record linkage to other health registers gives from an international perspective good opportunities to explore drug and disease associations and the risks, benefits, effectiveness and health economical effects of drug use. Copyright © 2006 John Wiley & Sons, Ltd.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.